Doxorubicin and Cyclophosphamide Mode of Chemotherapy-Related Cardiomyopathy: Review of Preclinical Model

Doxorubicin and Cyclophosphamide Mode of Chemotherapy-Related Cardiomyopathy: Review of Preclinical Model Publisher Pubmed

Avagimyan A^{1, 7} ; Kakturskiy L² ; Pogosova N³ ; Ottaviani G⁵ ; Rizzo M⁶ ; Sarrafzadegan N^{1, 7}

Show Affiliations

1. Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran
2. A.P. Avtsyn Research Institute of Human Morphology, Moscow, Russian Federation
3. National Medical Research Centre of Cardiology after acad. E. I. Chazov, Moscow, Russia
4. Peoples' Friendship University of Russia after Patrice Lumumba (RUDN), Moscow, Russia
5. Lino Rossi Research Center, Universita degli Studi di Milano, Milan, Italy
6. Universita degli Studi di Palermo, Palermo, Italy
7. Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran
8. University of British Columbia, Vancouver, Canada

Source: Current problems in cardiology Published:2025

Abstract

Over the past 70 years, there has been extensive research focused on preventing chemotherapy-related cardiovascular complications. However, the current state of cardio-oncology research has raised more questions than answers. Experimental studies often present data that are difficult to compare and, at times, contradictory. One notable limitation in translating experimental findings to clinical practice is the reliance on models that administer only one chemotherapeutic drug to experimental animals, despite the common use of multidrug cancer treatments in real clinical settings. This article aims to discuss our own experience in modeling an experimental rat model of cardiomyopathy induced by the administration of two chemotherapeutic drugs, doxorubicin (adriamycin) and cyclophosphamide (AC mode of chemotherapy) - Avagimyan A., et al model, along with a subsequent review of morphological changes based on our personal archive. Copyright © 2024. Published by Elsevier Inc.

Related Docs

View other Related Docs

1. Comparison of Cardioprotective Effects of Dapagliflozin and Trimetazidine in the Model of Doxorubicin-Cyclophosphamide Cardiotoxicity; [Сравнительная Характеристика Кардиопротекторных Эффектов Дапаглифлозина И Триметазидина На Модели Доксорубицин-Циклофосфамидной Кардиотоксичности], Innovative Medicine of Kuban (2023)

2. Possibilities of Dapagliflozin-Induced Cardioprotection on Doxorubicin + Cyclophosphamide Mode of Chemotherapy-Induced Cardiomyopathy, International Journal of Cardiology (2023)

3. Doxorubicin-Related Cardiotoxicity: Review of Fundamental Pathways of Cardiovascular System Injury, Cardiovascular Pathology (2024)

4. Pharmacological Interventions for Preventing Anthracycline-Induced Clinical and Subclinical Cardiotoxicity: A Network Meta-Analysis of Metastatic Breast Cancer, Journal of Oncology Pharmacy Practice (2021)

5. Trimetazidine As a Modifier of Chemotherapy-Induced Cardiovascular Redox-Homeostasis Disturbances, Kardiologija v Belarusi (2022)

6. Anthracycline Associated Disturbances of Cardiovascular Homeostasis, Current Problems in Cardiology (2022)

7. Genetically Engineered Mouse Embryonic Stem Cell-Derived Cardiomyocytes As a Suitable Model on Drugs Toxicity Assessment in Vitro, Journal of Isfahan Medical School (2014)

8. Cardioprotective Potential of Protocatechuic Acid Against Doxorubicin-Induced Cardiotoxicity in Rats, Research in Pharmaceutical Sciences (2025)

Experts (# of related papers)

View all Related Experts

Nizal Sarrafzadegan (5)

Davood Shafie (2)

Style	Citing Format
MLA	Avagimyan A, et al.. "Doxorubicin and Cyclophosphamide Mode of Chemotherapy-Related Cardiomyopathy: Review of Preclinical Model." Current problems in cardiology, vol. 50, no. 1, 2025, pp. 102882-.
APA	Avagimyan A, Kakturskiy L, Pogosova N, Ottaviani G, Rizzo M, Sarrafzadegan N (2025). Doxorubicin and Cyclophosphamide Mode of Chemotherapy-Related Cardiomyopathy: Review of Preclinical Model. Current problems in cardiology, 50(1), 102882-.
Chicago	Avagimyan A, Kakturskiy L, Pogosova N, Ottaviani G, Rizzo M, Sarrafzadegan N. "Doxorubicin and Cyclophosphamide Mode of Chemotherapy-Related Cardiomyopathy: Review of Preclinical Model." Current problems in cardiology 50, no. 1 (2025): 102882-.
Harvard	Avagimyan A et al. (2025) 'Doxorubicin and Cyclophosphamide Mode of Chemotherapy-Related Cardiomyopathy: Review of Preclinical Model', Current problems in cardiology, 50(1), pp. 102882-.
Vancouver	Avagimyan A, Kakturskiy L, Pogosova N, Ottaviani G, Rizzo M, Sarrafzadegan N. Doxorubicin and Cyclophosphamide Mode of Chemotherapy-Related Cardiomyopathy: Review of Preclinical Model. Current problems in cardiology. 2025;50(1):102882-.
BibTex	@article{ author = {Avagimyan A and Kakturskiy L and Pogosova N and Ottaviani G and Rizzo M and Sarrafzadegan N}, title = {Doxorubicin and Cyclophosphamide Mode of Chemotherapy-Related Cardiomyopathy: Review of Preclinical Model}, journal = {Current problems in cardiology}, volume = {50}, number = {1}, pages = {102882-}, year = {2025} }
RIS	TY - JOUR AU - Avagimyan A AU - Kakturskiy L AU - Pogosova N AU - Ottaviani G AU - Rizzo M AU - Sarrafzadegan N TI - Doxorubicin and Cyclophosphamide Mode of Chemotherapy-Related Cardiomyopathy: Review of Preclinical Model JO - Current problems in cardiology VL - 50 IS - 1 SP - 102882 EP - PY - 2025 ER -

Science Communicator Platform

Authors

Authors Affiliations

Abstract